MIAMI--(BUSINESS WIRE)--OPKO Health, Inc. (NYSE AMEX:OPK) has agreed to make an investment in Cocrystal Discovery, Inc., a privately held biopharmaceutical company focusing initially on the discovery and development of novel antiviral drugs for diseases for which current therapies are not adequate. The first targets are the viruses that cause the common cold and hepatitis C. While the current drug discovery effort is focused on pathogenic viruses, the Cocrystal technology can also be applied to other targets of medical importance.
